Immunotherapy Combos May Change Prognosis of Late-state or Recurrent EC

April 22nd 2021, 12:41pm


The researchers focused on immunotherapy combinations, which they say may hold promise in the treatment of late-stage or recurrent endometrial cancer (EC).

First Immunotherapy for Initial Treatment of Gastric Cancer Approved

April 19th 2021, 11:00pm


Nivolumab, marketed under the name Opdivo, led to a 29% reduced risk of death when combined with certain chemotherapies for gastric cancers.

Avalere Report Looks at Geographic Challenges to Accessing CAR T-Cell Therapies

April 17th 2021, 1:29am


Given that some patients may need to travel out of state to access CAR T sites of care, some may not have a clear understanding of their insurance benefits, including requirements for out-of-state or out-of-network treatment, as well as adequate assistance with the costs of medical-related travel.

“Speckle” Structures Believed to Partner With p53 in Cancer Activity

April 10th 2021, 12:15pm


The study identifies the tumor-suppressing protein p53 as a working partner of “speckles,” nuclear structures that contain proteins and RNA involved in gene expression.

Challenges, Opportunities for Improvement Persist in CAR T-Cell Treatment

April 2nd 2021, 3:15pm


As more therapies continue to be approved, efforts will focus on toxicity prevention and mitigation strategies for associated unique and potentially life-threatening adverse reactions.

FDA Approves Idecabtagene Vicleucel for Multiple Myeloma

March 27th 2021, 7:00pm


The approval marks the first B-cell maturation antigen-directed genetically modified autologous chimeric antigen receptor T-cell therapy for patients with relapsed or refractory multiple myeloma.

The Expanding Landscape of Immunotherapy in Urothelial Bladder Cancer

March 25th 2021, 8:00pm


At the National Comprehensive Cancer Network Annual Conference, Arlene O. Siefker-Radtke, MD, discussed immune checkpoint inhibitors and their potential in urothelial bladder cancer.

Looking at Long-term Results, New Opportunities With CAR T-Cell Therapies

March 20th 2021, 6:46pm


Penn Medicine's Stephen Schuster, MD, offers an overview of an eventful year in CAR T-cell therapy at the NCCN Virtual Annual Meeting.

Axi-cel May Add Years, Decrease Cost vs Tisa-cel in Large B-Cell Lymphoma

March 18th 2021, 1:00pm


A new cost-effectiveness analysis suggests quality-adjusted life year gain and cost reduction for patients treated with axicabtagene ciloleucel versus tisagenlecleucel.

FDA to Reassess 6 Oncology Immunotherapy Indications Granted Accelerated Approval

March 12th 2021, 10:00pm


The FDA will reassess 6 indications for immune checkpoint inhibitors that were granted accelerated approval but failed to prove clinical benefit in confirmatory trials.